Cargando…
The IgG-degrading enzyme, Imlifidase, restores the therapeutic activity of FVIII in inhibitor-positive hemophilia A mice.
Neutralizing anti-factor VIII (FVIII) antibodies, known as FVIII inhibitors, represent a major drawback of replacement therapy in persons with congenital hemophilia A (PwHA), rendering further infusions of FVIII ineffective. FVIII inhibitors can also appear in non-hemophilic individuals causing acqu...
Autores principales: | Bou-Jaoudeh, Melissa, Delignat, Sandrine, Daventure, Victoria, Astermark, Jan, Lévesque, Hervé, Dimitrov, Jordan D, Deligne, Claire, Proulle, Valérie, Lacroix-Desmazes, Sébastien |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10153532/ https://www.ncbi.nlm.nih.gov/pubmed/36655430 http://dx.doi.org/10.3324/haematol.2022.281895 |
Ejemplares similares
-
Complement protein C3a enhances adaptive immune responses towards FVIII products
por: Ringler, Eva, et al.
Publicado: (2023) -
Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell disease
por: Rossato, Paolo, et al.
Publicado: (2022) -
Relapse of immune-mediated thrombotic thrombocytopenic purpura following mRNA COVID-19 vaccination: a prospective cohort study
por: Giuffrida, Gaetano, et al.
Publicado: (2022) -
Translational readthrough at F8 nonsense variants in the factor VIII B domain contributes to residual expression and lowers inhibitor association
por: Testa, Maria Francesca, et al.
Publicado: (2022) -
APOLD1 loss causes endothelial dysfunction involving cell junctions, cytoskeletal architecture, and Weibel-Palade bodies, while disrupting hemostasis
por: Stritt, Simon, et al.
Publicado: (2022)